Volume 9, Number 1—January 2003
Research
Shiga Toxin–Producing Escherichia coli Infections Associated with Hemolytic Uremic Syndrome, Italy, 1988–2000
Table
Evidence of STEC infection | Patients with symptoms
no. positive/no. examined (%) |
|||||
---|---|---|---|---|---|---|
Bloody diarrhea | Nonbloody diarrhea | No diarrhea | No information | Total | ||
STEC isolation |
9/88 (10.2) |
4/63 (6.3) |
4/39 (10.2) |
1/38 (2.6) |
18/228 (7.9) |
|
Free fecal Stx |
23/86 (26.7) |
21/63 (33.3) |
10/38 (26.3) |
9/38 (23.7) |
63/225 (28.0) |
|
Antibodies to LPS |
61/88 (69.3) |
39/63 (61.9) |
14/41 (34.1) |
30/43 (69.8) |
144/235 (61.3) |
|
Any | 73/92 (79.3) | 50/67 (74.6) | 22/42 (52.4) | 37/48 (77.1) | 182/249 (73.1) |
aSTEC, Shiga toxin–producing Escherichia coli; HUS, hemolytic uremic syndrome; Stx, Shiga toxin; LPS, lipopolysaccharide.
1Members of the Hemolytic Uremic Syndrome Study Group are: A. Bettinelli, G. Capasso, A. Caringella, R. Coppo, G. Lama, S. Li Volti, S. Maffei, S. Maringhini, N. Miglietti, C. Pecoraro, I. Pela, M. Pennesi, R. Penza, L. Peratoner, F. Perfumo, I. Ratsche, E. Salvaggio, C. Setzu, and G. Zacchello.
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.